Search results for "Ki-67 Antigen"

showing 10 items of 78 documents

Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papil…

2019

Objectives: To investigate the expression of several immunohistochemical (IHC) markers and their predictive ability for the recurrence-free and progression-free survival of papillary urothelial bladder cancer (UBC) pTa/pT1 G2 (WHO 1973) compared to classical anatomo-clinical variables using a multidimensional analysis. Materials and Methods: A population-based cohort of 213 primary stage UBC (pTa/pT1) G2 (WHO 1973) was evaluated by classic anatomopathological variables and characterized by immunohistochemistry (23 IHC markers, representative of different oncogenic pathways). The most important variables as a predictor of recurrence-free and progression-free survival were selected using mult…

MaleOncologymedicine.medical_specialtyMultidimensional analysisSurvivinUrologyPopulation030232 urology & nephrologyCohort Studies03 medical and health sciences0302 clinical medicineCyclin D1Stage Ta/T1Predictive Value of TestsInternal medicineSurvivinBiomarkers TumormedicineHumansCyclin D1Progression-free survivalStage (cooking)educationCyclin-Dependent Kinase Inhibitor p16AgedNeoplasm Stagingeducation.field_of_studyBladder cancerbiologybusiness.industryClinical outcomeBladder cancerMiddle Agedmedicine.diseaseImmunohistochemistryCarcinoma PapillarySurvival RateKi-67 AntigenUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisKi-67biology.proteinImmunohistochemistryFemaleNeoplasm GradingNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Speci…

2005

Abstract Purposes: To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility. Material and methods: The IHC study was carried out in 91 patients operated by means of radical prostatectomy (RP) with available formalin-fixed paraffin-embedded material from both C and SP. Results: The IHC expression of Bcl-2 in C and SP was very low (5%). Bax was expressed in almost all the patients and did not show any prognostic value. We observed a good reproducibility between C and SP for all molecules except with Bax. In prostate C,…

MaleOncologymedicine.medical_specialtyPathologyBiopsyUrologymedicine.medical_treatmentDisease-Free SurvivalProstate cancerProstateInternal medicineBiopsyBiomarkers TumormedicineHumansAgedRetrospective Studiesbcl-2-Associated X ProteinProstatectomyUnivariate analysismedicine.diagnostic_testbiologyProstatectomybusiness.industryMembrane ProteinsProstatic NeoplasmsAnatomical pathologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistryKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2Cyclooxygenase 2Ki-67Multivariate AnalysisDisease Progressionbiology.proteinImmunohistochemistrybusinessEuropean Urology
researchProduct

Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers.

2005

Aims:  To evaluate the clinicopathological and immunohistochemical characteristics of Merkel cell carcinoma (MCC) in an attempt to find new, potentially significant, prognostic markers. Methods and results:  Clinical data and follow-up, histopathological features (pattern, cell size, thickness, mitoses, vascular invasion, lymphocytic infiltration) and immunohistochemical detection [CK20, thyroid transcription factor (TTF-1), chromogranin A, synaptophysin, p53, Ki67, Fli-1, CD99, c-Kit] were evaluated in 20 cases of MCC. Fli-1 and CD99 were detected in 90% and 55% of cases, respectively. Tumour size > 30 mm, stage II, ‘absent’ lymphocytic infiltration, and the presence of > 50% of Ki67+ tumo…

MalePathologyThyroid Nuclear Factor 1Keratin-20Intermediate Filament ProteinsLymph nodeAged 80 and overbiologyMerkel cell carcinomaChromogranin ANuclear ProteinsGeneral MedicineMiddle AgedPrognosisImmunohistochemistryDNA-Binding ProteinsProto-Oncogene Proteins c-kitmedicine.anatomical_structureFemaleMerkel cellmedicine.medical_specialtyHistologyCD99Synaptophysin12E7 AntigenPathology and Forensic MedicineAntigens CDProto-Oncogene ProteinsCarcinomamedicineBiomarkers TumorChromograninsHumansSurvival analysisAgedNeoplasm StagingProto-Oncogene Protein c-fli-1Keratin 20medicine.diseaseSurvival AnalysisCarcinoma Merkel CellMicroscopy ElectronKi-67 AntigenMultivariate Analysisbiology.proteinTrans-ActivatorsChromogranin ANeoplasm Recurrence LocalTumor Suppressor Protein p53Cell Adhesion MoleculesFollow-Up StudiesTranscription FactorsHistopathology
researchProduct

Pediatric High-Grade Astrocytomas Show Chromosomal Imbalances Distinct from Adult Cases

2001

We studied 23 pediatric high-grade astrocytomas by comparative genomic hybridization. Chromosomal imbalances were found in 10 of 10 anaplastic astrocytomas and 11 of 13 glioblastomas and consisted of +1q (43%), +3q (26%), +1p, +2q, +5q (22%), −22q (34%), −6q, −10q (30%), −9q, −11q, −13q, −16q, and −17p (22%). Anaplastic astrocytomas frequently showed +5q (40%), +1q (30%), −22q (50%), −6q, −9q (40%), and −12q (30%); glioblastomas +1q (54%), +3q (38%), +2q, +17q (23%), −6q, −8q, −10q, −13q, and −17p (31%). Minimal common regions mapped to +1q21-41, +3q27-qter, +2q31-32, +5q14-22, −22q12-qter, −10q23-25, −6q25-qter, −9q34.2, −11q14−22, −16q22-qter, and −17p. High-level gains were located on 1q…

MalePathologymedicine.medical_specialtyAdolescentGene DosageAstrocytomaBiologyGastroenterologyPathology and Forensic MedicineInternal medicinemedicineHumansChildChromosome AberrationsBrain NeoplasmsInfantNucleic Acid HybridizationAstrocytomamedicine.diseaseSurvival AnalysisKi-67 AntigenChild PreschoolFemaleGlioblastomaCell DivisionRegular ArticlesGlioblastomaAnaplastic astrocytomaThe American Journal of Pathology
researchProduct

Cyclooxygenase-2 Expression Is Related With Localization, Proliferation, and Overall Survival in Canine Melanocytic Neoplasms

2011

A direct relationship has been firmly established between cyclooxygenase-2 (COX-2) expression and malignant behavior in human melanoma. This report examines the relationship between COX-2 expression and tumor location, mitotic and proliferative indices, degree of T CD3+ lymphocyte infiltration, overall survival, and frequency of recurrence and metastasis of 57 melanocytic tumors (25 oral and 32 cutaneous). COX-2 was highly or moderately expressed in 88% of oral neoplasms (22 of 25), whereas for their cutaneous counterparts, COX-2 expression was low or insignificant in 75% of cases (24 of 32). High and moderate COX-2 expression levels were observed in 73% of melanocytic tumors with a mitoti…

MalePathologymedicine.medical_specialtySkin NeoplasmsMitotic indexCD3MetastasisDogsBiomarkers TumorMitotic IndexmedicineAnimalsDog DiseasesMelanomaMitosisSurvival analysisRetrospective StudiesRegulation of gene expressionGeneral Veterinarybiologybusiness.industryMelanomamedicine.diseaseSurvival AnalysisGene Expression Regulation NeoplasticKi-67 AntigenCyclooxygenase 2biology.proteinFemaleMouth NeoplasmsCyclooxygenasebusinessFollow-Up StudiesVeterinary Pathology
researchProduct

Connexin 43, Bcl-2, Bax, Ki67, and E-cadherin patterns in oral squamous cell carcinoma and its relationship with GJA1 rs12197797 C/G

2022

To our knowledge, there is no useful and accurate prognostic biomarker or biomarkers for patients with oral squamous cell carcinoma (OSCC), a tumor with uncertain biological behavior, and unpredicTable clinical progress. The purposes of this study were: a) to determine the expresión profile of Connexin 43, Bcl-2, Bax, E-cadherin, and Ki67 in patients with OSCC; b) identify the GJCA1 rs12197797 genotypic composition. A cross-sectional study using genomic DNA and biopsy samples extracted from the oral mucosa with/without OSCC, older than 18 years, both genders, attended at Facultad de Odontología, Universidad Nacional Córdoba. Immunostaining for Cx43, Bcl-2, Bax, E-cadherin, and Ki67 and geno…

MaleSquamous Cell Carcinoma of Head and Neckgapsendoscopeopaque dentinCadherinsperiapical surgeryCross-Sectional StudiesKi-67 AntigenProto-Oncogene Proteins c-bcl-2OtorhinolaryngologyHead and Neck NeoplasmsConnexin 43Biomarkers TumorCarcinoma Squamous CellHumansFemaleMouth NeoplasmscracksSurgeryGeneral DentistryUNESCO:CIENCIAS MÉDICASbcl-2-Associated X ProteinMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

2007

Background and aims: increased epithelial cell proliferation may be detected in diverticular disease, but antibiotics have failed in reducing it. We assess therefore the effect of mesalazine on epithelial cell proliferation in diverticular disease. Methods: a prospective study was conducted on 20 consecutive patients with a new endoscopic diagnosis of symptomatic uncomplicated diverticular disease. The patients were treated with mesalazine 1.6 mg/day for 1 year. The Ki-67 antigen index of the whole crypt and in the upper third was separately evaluated before and after starting the treatment. Results: cell proliferation index was higher in diverticular disease patients than healthy controls …

Malediverticular diseaseSeverity of Illness IndexGastroenterologychemistry.chemical_compoundReference ValuesProspective StudiesIntestinal MucosaMesalamineProspective cohort studyCell proliferationtreatmentmedicine.diagnostic_testAnti-Inflammatory Agents Non-SteroidalBiopsy Needledigestive oral and skin physiologyGastroenterologyColonoscopyMiddle AgedImmunohistochemistryDiverticulosisDose–response relationshipTreatment OutcomemesalazineDiverticular diseaseFemalemedicine.medical_specialtyCryptRisk Assessmentdigestive systemDrug Administration ScheduleStatistics NonparametricMesalazineInternal medicineBiopsyDiverticulosis ColonicmedicineHumansAgedProbabilityDose-Response Relationship DrugHepatologybusiness.industryCase-control studyEpithelial Cellsmedicine.diseasedigestive system diseasescolonic mucosaKi-67 AntigenchemistryCase-Control StudiesbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet.

2013

Endogenous glucagon-like peptide-2 (GLP2) is a key mediator of refeeding-induced and resection-induced intestinal adaptive growth. This study investigated the potential role of GLP2 in mediating the mucosal responses to a chronic high-fat diet (HFD). In this view, the murine small intestine adaptive response to a HFD was analyzed and a possible involvement of endogenous GLP2 was verified using GLP2 (3–33) as GLP2 receptor (GLP2R) antagonist. In comparison with animals fed a standard diet, mice fed a HFD for 14 weeks exhibited an increase in crypt–villus mean height (duodenum, 27.5±3.0%; jejunum, 36.5±2.9%;P<0.01), in the cell number per villus (duodenum, 28.4±2.2%; jejunum, 32.0±2.9%;P&l…

Malemedicine.medical_specialtyDuodenumEndocrinology Diabetes and MetabolismEndogenyBiologyDiet High-Fatdigestive systemJejunumMiceEndocrinologyInternal medicineIntestine SmallmedicineGlucagon-Like Peptide 2Receptors GlucagonAnimalsMolecular Targeted TherapyObesityIntestinal MucosaReceptorCell ProliferationCell growthdigestive oral and skin physiologyGLP2 receptor expression intestinal morphometry obesity intestinal adaptationGlucagon-like peptide-2Adaptation PhysiologicalSmall intestinePeptide FragmentsUp-RegulationMice Inbred C57BLEndocrinologymedicine.anatomical_structureJejunumKi-67 AntigenDuodenumGlucagon-Like Peptide-2 ReceptorAnti-Obesity AgentsGlucagon-Like Peptide-2 ReceptorSignal TransductionThe Journal of endocrinology
researchProduct

Lymph node metastases displaying lower Ki-67 immunostaining activity than the primary breast cancer

2007

The aim of the study was to verify by Ki-67 immunostaining if any difference exists in the cell proliferating fraction between primary breast tumors (PTs) and matching positive axillary lymph nodes (ALNs). PATIENTS AND METHODS: Immunohistochemistry with the monoclonal antibody against Ki-67 was performed in 160 node-positive breast carcinomas and in their respective lymph node metastases. RESULTS: An increase of Ki-67 immunoreactive cells in ALN compared with that of PTs was observed in 84% of cases (ALN: mean 17%, PTs: mean 8%; p < 0.001), whereas 16% of the cases showed Ki-67 value two to six times lower in the ALNs than in the corresponding PTs (ALN: mean 3.2%, PTs mean 12.5%; p < 0.005)…

Metastases; Immunohistochemistry; Breast cancerBreast cancerKi-67 AntigenLymphatic MetastasisMetastaseHumansBreast NeoplasmsFemaleSettore MED/08 - Anatomia PatologicaImmunohistochemistry
researchProduct

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…

2015

Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…

OncologyAdultAdjuvant taxanesCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmenteducationBreast NeoplasmsDocetaxelDisease-Free SurvivalPooled analysisBreast cancerBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIn patientAnthracyclinesOestrogen receptorProspective StudiesAgedER positivebusiness.industryMiddle Agedmedicine.diseaseImmunohistochemistryPooled analysisKi-67 AntigenOncologyDocetaxelBreast international groupChemotherapy AdjuvantFemaleTaxoidsbusinessAdjuvantKi67medicine.drug
researchProduct